Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...

A former Keolis engineer has pleaded guilty to wire fraud and tax evasion, admitting to stealing over $8 million from MBTA Commuter Rail funds, with sentencing in April.

A man has been arrested by the United States Marshals Service for the fatal crash in Urbana that took the lives of two women.

New Activin R-based medications can emerge as perfect solutions for balancing weight loss and muscle building, making a ...

Argus lowered the firm’s price target on Novo Nordisk (NVO) to $110 from $140 but keeps a Buy rating on the shares and contends that the ...

Novo Nordisk, in particular, has been a strong competitor with its semaglutide products. As more players enter the market, Eli Lilly may face pressure on pricing and market share. If competitors ...

Deep-pocketed investors have adopted a bearish approach towards Eli Lilly LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

The FDA also warned consumers not to use counterfeit semaglutide in 2023 ... Pharmaceutical giants Eli Lilly and Novo Nordisk, makers of Zepbound and Wegovy, respectively, have filed lawsuits ...

Approval was based on results of the VIVID-1 study, which found that Omvoh demonstrated significant clinical remission and endoscopic response rates in patients with Crohn disease. The FDA has ...

Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of around $720 billion. For a while, it looked like it might be on track to be the first ...

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $996.00. The company’s shares closed yesterday ...